ReviewCancers2022
Current and Emerging Methods for Ovarian Cancer Screening and Diagnostics: A Comprehensive Review.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
78 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Survival Patterns of Patients with Ovarian Cancer in Africa: Systematic Review and Meta-analysis.Annals of surgical oncology · 2026Pooled it
- Emerging nanotechnologies and their role in early ovarian cancer detection, diagnosis and interventions.Journal of ovarian research · 2025Pooled it
- DNA methylation biomarkers for early detection of ovarian cancer.Molecular biology reports · 2026Review
- Depth-sensitive optical property characterization using multi-frequency laparoscopic spatial frequency domain imaging.Biomedical optics express · 2026Article
- Enhancing the positive predictive value of early-stage ovarian cancer detection using a two-step machine learning framework.Journal of translational medicine · 2026Article
- Comparative Analysis of Serum and Tissue miRNA Expression Profiles and Regulatory Pathways in Early-Stage Ovarian Cancer Using Public Databases.International journal of molecular sciences · 2026Article
- A Rational Optimization Approach for the Development of a Multiplexed Lateral Flow Immunoassay: Detection of Nonepithelial Ovarian Cancer Markers in Human Serum.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Emerging Near-Infrared Targeted Imaging Pharmaceutics for Ovarian Cancer.Pharmaceutics · 2026Review
- A machine learning-based basement membrane gene signature model for predicting ovarian cancer survival.Translational cancer research · 2026Article
- Study of Estrogen Receptor Alpha Gene Polymorphisms (International journal of molecular sciences · 2026Article
- A bioinformatics approach to identify potential biomarkers of high-grade ovarian cancer.Journal of the Turkish German Gynecological Association · 2026Article
- Integrative bioinformatics approaches for early detection biomarkers in ovarian cancer.Annals of medicine and surgery (2012) · 2026Review
- Recent advances in nanomaterial-based precision medicine for orthotopic tumor therapy.Journal of nanobiotechnology · 2026Review
- Recent Update Targeting Autophagy-Apoptosis Crosstalk Using Bioactive Natural Products for Ovarian Cancer Treatment.Biomedicines · 2026Review
- IAPs in cancers: molecular mechanisms, clinical prognostic value, and translational therapeutic potential.Journal of translational medicine · 2026Review
- Label-free electrochemiluminescence aptasensing platform: Au-LDH-CMikrochimica acta · 2026Article
- Clinical factors influencing serum CA125 levels and their implications for diagnosing ovarian tumors.Bioinformation · 2026Article
- Single-Cell-Derived Malignant Epithelial Programs Define Prognostic Risk and Therapeutic Vulnerability in Ovarian Cancer.Journal of Cancer · 2026Article
- Article
- U-shaped prognostic signature: baseline platelet count and morphological parameters predict ovarian cancer outcomes in a 265-patient cohort.Frontiers in oncology · 2026Article
18 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
With a 5-year survival rate of less than 50%, ovarian high-grade serous carcinoma (HGSC) is one of the most highly aggressive gynecological malignancies affecting women today. The high mortality rate of HGSC is largely attributable to delays in diagnosis, as most patients remain undiagnosed until the late stages of -disease. There are currently no recommended screening tests for ovarian cancer and there thus remains an urgent need for new diagnostic methods, particularly those that can detect the disease at early stages when clinical intervention remains effective. While diagnostics for ovarian cancer share many of the same technical hurdles as for other cancer types, the low prevalence of the disease in the general population, coupled with a notable lack of sensitive and specific biomarkers, have made the development of a clinically useful screening strategy particularly challenging. Here, we present a detailed review of the overall landscape of ovarian cancer diagnostics, with emphasis on emerging methods that employ novel protein, genetic, epigenetic and imaging-based biomarkers and/or advanced diagnostic technologies for the noninvasive detection of HGSC, particularly in women at high risk due to germline mutations such as
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.